On eve of JPM, everything’s coming up Big Pharma

Taking stock of the drug industry, from the lab to the medicine chest

January 7, 2026 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

BRENDAN SMIALOWSKI/AFP via Getty Images STAT+ | On eve of JPM, everything's coming up Big Pharma After a year of 'wild whiplash' and pricing deals with the White House, drug companies approach JPM 2026 with confidence that 'there are deals to be done.' By Damian Garde Opinion: RFK Jr.'s war on antidepressants is coming — and it will cost lives Well-intended but mismanaged warnings about possible SSRIs have already cost several thousand lives, experts write. By Stephen B. Soumerai and Christine Y. Lu STAT+ | China expected to soon surpass U.S. in bio innovation Today's biotech news includes China to soon surpass U.S. in bio innovation, Lilly reportedly in talks to acquire Ventyx, and more. By Elaine Chen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2026, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser